A5045551199- Metal complexes synthesis and properties
- Click Chemistry and Applications
- X-ray Diffraction in Crystallography
- Crystallization and Solubility Studies
- Synthesis and Characterization of Heterocyclic Compounds
- Synthesis and biological activity
- Synthesis of Tetrazole Derivatives
- Sarcoma Diagnosis and Treatment
- Metal-Catalyzed Oxygenation Mechanisms
- Mast cells and histamine
- Luminescence and Fluorescent Materials
- Colorectal and Anal Carcinomas
- Lymphoma Diagnosis and Treatment
- Lanthanide and Transition Metal Complexes
- Photodynamic Therapy Research Studies
- melanin and skin pigmentation
- Metalloenzymes and iron-sulfur proteins
- Nonmelanoma Skin Cancer Studies
- Cardiac tumors and thrombi
- Synthesis and Biological Evaluation
- Nanoplatforms for cancer theranostics
- Melanoma and MAPK Pathways
Universidad de Murcia
2020-2024
Instituto Murciano de Investigación Biosanitaria
2020
Centro de Salud Casa del Barco
2019
Hospital General San Jorge
2019
Hospital Universitario Miguel Servet
2014-2016
Photodynamic therapy (PDT) represents a promising approach for cancer treatment. However, the oxygen dependency of PDT to generate reactive species (ROS) hampers its therapeutic efficacy, especially against hypoxic solid tumors. In addition, some photosensitizers (PSs) have dark toxicity and are only activatable with short wavelengths such as blue or UV-light, which suffer from poor tissue penetration. Herein, we developed novel hypoxia-active PS operability in near-infrared (NIR) region...
A second-generation series of biscyclometalated 2-(5-aryl-thienyl)-benzimidazole and -benzothiazole Ir(III) dppz complexes [Ir(C^N)2(dppz)]+, Ir1–Ir4, were rationally designed synthesized, where the aryl group attached to thienyl ring was p-CF3C6H4 or p-Me2NC6H4. These new assessed as photosensitizers explore structure–activity correlations for their potential use in biocompatible anticancer photodynamic therapy. When irradiated with blue light, exhibited high selective potency across...
We designed a series of pseudo-octahedral arene Os(II) complexes ( Os1 – Os5 ) with the general formula [(η 6 - p -cym)Os(BTAT)Cl] + , where BTAT represents chelating N^N′ ligands based on 1-aryl-4-benzothiazolyl-1,2,3-triazole scaffold. The structures Os3 ...
Ruthenium(II) complexes containing diimine ligands have contributed to the development of agents for photoactivated chemotherapy. Several approaches been used obtain photolabile Ru(II) complexes. The two most explored use monodentate and incorporation steric effects between bidentate Ru(II). However, introduction electronic in has less explored. Herein, we report a systematic experimental, theoretical, photocytotoxicity study novel series Ru1–Ru5 general formula [Ru(phen)2(N∧N′)]2+, where...
A new generation of benzimidazole-based cyclometalated ruthenium( ii ) complexes with bpy or dpq as ancillary ligands are effective against hypoxic cancers via green light activation and can directly disrupt phospholipid membranes trigger oncosis.
We present the synthesis and characterization of six new heteroleptic osmium(II) complexes type [Os(C^N)(N^N)2]OTf (N^N = 2,2'-bipyridine dipyrido[3,2-d:2',3'-f]quinoxaline; C^N deprotonated methyl 1-butyl-2aryl-benzimidazolecarboxylate) with varying substituents in R3 position phenyl ring cyclometalating ligand. The compounds are highly kinetically inert absorb a full-wavelength range visible light. An investigation antiproliferative activity has been performed using panel human cancer...
Novel Os(<sc>ii</sc>) arene complexes with a deprotonated ppy or ppy-CHO C^N ligand have been synthesized to selectively act on cancer cells as proteosynthesis inhibitors<italic>in vitro</italic>and exert antitumor activity<italic>in vivo</italic>in<italic>C. elegans</italic>models.
The Ewing's sarcoma family of tumors (ESFT) comprises a number rare malignant tumors. Standard first-line treatment for patients with these includes chemotherapy five-drug regimen vincristine, doxorubicin (Adriamycin®) and cyclophosphamide, alternating ifosfamide etoposide (VAC/IE). In cases inadequate response, there are second-line regimens available. However, further options required those disease unresponsive to standard treatment. Trabectedin is novel option ESFT. present study reports...
Anal cancer is a rare tumor that accounts for 2% of all colorectal neoplasms. The brain rarely affected organ. aim the present study was to review only four cases anal metastases previously published in literature. In addition, current presents case 69‑year‑old male diagnosed with basaloid undifferentiated carcinoma canal (stage IV liver, lung and bone metastasis). Despite patient's good response chemotherapy achievement partial maintained 14 months, developed. Although radiotherapy...
Anti-programmed cell death (PD)-1 therapies in metastatic tumors have a high incidence of immune adverse events, including cutaneous manifestations such as vitiligo-like lesions. This side effect is associated with increased survival and it clinical marker response to treatment. case report graphic representation the appearance lesions over in-transit metastases malignant melanoma linked complete treatment pembrolizumab.
We present the synthesis and characterization of six new heteroleptic osmium(II) complexes type [Os(C^N)(N^N) 2 ]OTf (N^N = 2,2′-bipyridine, dipyrido[3,2-d:2',3'-f]quinoxaline; C^N deprotonated methyl 1-butyl-2aryl-benzimidazolecarboxylate) with varying substituents in R3 position phenyl ring cyclometalating ligand. The compounds are highly kinetically inert absorb a full-wavelength range visible light. An investigation antiproliferative activity has been performed using panel human cancer...